

November 4, 2025

To,

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	National Stock Exchange of India Limited “Exchange Plaza” Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET
---	--

Sub: Analysts/Investors Presentation on Financial Results for the quarter and half year ended September 30, 2025

Dear Sir / Ma'am,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Analysts/Investors Presentation on the Financial Results for the quarter and half year ended September 30, 2025 to be held today, i.e. on November 4, 2025.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Blue Jet Healthcare Limited**

Sweta Poddar
Company Secretary & Compliance Officer

Unit I

3/2, Milestone, Kalyan Murbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, Tel.: 91 251 2280283 Fax : +91 251 2280567

Unit II

Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambarnath (W) 421501. Tel. : +91 8956363877/8956363878

Unit III

K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, Tel.: + 91 22 2207 5307 / 6192 / 1691 Fax : +91 22 2207 0294

Investor Presentation

Q2 & H1 FY26



Disclaimer



The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Blue Jet Healthcare Ltd.



Table of Content



- 1 Q2 & H1 FY26 Financials
- 2 Company at a Glance
- 3 Contrast Media Intermediates
- 4 High Intensity Sweeteners
- 5 Pharma Intermediates & API
- 6 R&D Capabilities
- 7 Growth Strategy
- 8 Management and Board of Directors





1

Q2 & H1 FY26 Financials

Q2 FY26 Earnings Highlights



Financial Highlights

- ✓ **Revenue from Operation** in Q2 FY26 stood at Rs.1,655 mn, EBITDA stood at Rs. 549 mn (33% Margin) and PAT at Rs. 521 mn (32% Margin).
- ✓ **Revenue from Operation** in Q1 FY26 was Rs. 3,548 mn, EBITDA stood at Rs. 1,210 mn (34% Margin) and PAT at Rs. 912 mn (26% Margin).
- ✓ **On QoQ comparison**, Revenue from operations decreased by 53%, EBITDA margin decreased by 1% and PAT margin increased by 6% during Q2 FY26.
- ✓ **The decrease in revenues** during this quarter is due lower sales in PI segment entirely attributable to de-stocking of channel inventory .
- ✓ **Gross Margin** for Q2 FY26 was 65% Vs Q1 FY26 which was 48%. This was due to change in Inventory, higher levels of **finished goods (including goods in transit)** by Rs. 506 mn and **overhead allocation on the same had reduced COGS by (9%)** thereby having a positive impact on gross margin.
- ✓ **Robust other Income** during this quarter Rs. 243 mn increased by 194% [Rs 83 mn in Q1 FY26] mainly due to higher **net foreign exchange gain** of Rs. 154 mn on account USD appreciation and **treasury income** of Rs. 74 mn.



H1 FY25 Earnings Highlights



Financial Highlights

- ✓ **H1 FY26 Revenue from Operation** stood at **Rs. 5,202 mn**, EBITDA at **Rs. 1,759 mn (34% Margin)** and **PAT** at **Rs. 1,433 mn (28% Margin)**
- ✓ **H1 FY25 Revenue from Operations** was **Rs. 3,712 mn**, EBITDA at **Rs. 1,137 mn (31% Margin)** and **PAT** at **Rs. 961 mn (26% Margin)**
- ✓ **On YoY comparison**, Revenue from operations increased by **40%**, EBITDA increased by **55%** and **PAT** increased by **49%** during Q2 FY26.
- ✓ **Increase in revenue from operations** in **H1 FY26** is due to increase in sales of PI.
- ✓ **Gross Margin** for **H1 FY26** is at **54% Vs H1 FY25 at 56%..**
- ✓ **Other income** increased in **H1 FY26** by **56% [Rs. 325 mn]** as compared to **Rs. 208 mn** mainly due to higher net foreign exchange gain of **Rs. 111 mn** on account USD appreciation.
- ✓ **Free Cash & Cash equivalent and Treasury Investments stands** at **Rs. 3,413 Mn** as on 30 September 2025 as compared to **Rs. 2,848 Mn** as on 31st March 2025. This increase is due to unlocking of working capital.



Q2 & H1 FY25 Earnings Highlights



Business Updates

- ✓ **New Product launched - Iodinated based** advance contrast media intermediate dispatched during July 25.
- ✓ **NCE -Contrast media for MRI Segment** is reporting robust growth in regulated markets leading to a strong Order Book
- ✓ **RFPs for new products:** New RFPs received for one high conviction phase 3 and two for products already commercialized leading to potential Lateral entries
- ✓ **Key Intermediate in PI category** - end cardiovascular drug is showing good growth and traction in all geographies & consistent increase in prescriptions as per customer available data . This would result in commensurate growth of our product during life of the patent.
- ✓ **Payment for acquisition of land** of 102 acres at near Vizag has been made (Rs 42 crores) and further formalities are under process
- ✓ **Incurred capex investment of over Rs. 82 crore (other than land)** during the period April 25 to Sep 25 and the Project at Mahad backward integration is progressing well



Q2 FY26 Vs Q2 FY25 Financial Performance – Key Metrics



Revenue from Operations** – Growth Trends

(Rs Mn)

YoY
Growth:

7.4%


-28.8%

-27.1%

154.2%

-20.6%

■ Q2 FY25 ■ Q2 FY26



EBITDA Profile

■ EBITDA ■ EBITDA Margin (Rs Mn)

33.4%

33.2%

-20.9% YoY

Q2 FY25

Q2 FY26

695

549

PAT Profile

■ PAT ■ PAT Margin (Rs Mn)

28.0%

31.5%

-10.6% YoY

Q2 FY25

Q2 FY26

583

521

■ EPS

-10.6% YoY

Q2 FY25

Q2 FY26

3.4

3.0

- *Others include spent oils and industrial mix solvents
- **Excludes Other Operating Revenue





(*) Not annualized

H1 FY26 Vs H1 FY25 Financial Performance – Key Metrics



Revenue from Operations** – Growth Trends

(Rs Mn)



- *Others include spent oils and industrial mix solvents
- **Excludes Other Operating Revenue

Profit and Loss Statement




Particulars (Rs. Mn)	Q2 FY26	Q1 FY26	QoQ	Q2 FY25	YoY	H1 FY26	H1 FY25	YoY
Revenue from Operations	1,655	3,548	-53.4%	2,083	-20.5%	5,202	3,712	40.2%
Cost Of Goods Sold	579	1,829		895		2,408	1,633	
Gross Profit	1,076	1,719	-37.4%	1,187	-9.4%	2,795	2,078	34.5%
<i>Gross Margin</i>	<i>65.0%</i>	<i>48.4%</i>		<i>57.0%</i>		<i>53.7%</i>	<i>56.0%</i>	
Employee benefits expenses	186	174		154		360	302	
Other expenses	341	334		339		676	639	
Total Expenses	1,105	2,338		1,388		3,443	2,574	
EBITDA	549	1,210	-54.6%	695	-20.9%	1,759	1,137	54.7%
<i>EBITDA Margin</i>	<i>33.2%</i>	<i>34.1%</i>		<i>33.4%</i>		<i>33.8%</i>	<i>30.6%</i>	
Depreciation and amortization	59	57		46		116	81	
PBIT	734	1,236	-40.6%	769	-4.7%	1,969	1,264	55.7%
Exceptional Items	0	0		0		0	0	
Finance costs	46	7		0		53	0	
Other Income	243	83		121		325	208	
PBT	687	1,229	-44.1%	769	-10.7%	1,916	1,264	51.6%
Tax Expense	166	317		186		483	303	
PAT	521	912	-42.8%	583	-10.6%	1,433	961	49.1%
<i>PAT Margin</i>	<i>31.5%</i>	<i>25.7%</i>		<i>28.0%</i>		<i>27.5%</i>	<i>25.9%</i>	

Financial Performance over the years – Key Metrics



Revenue from Operations** – Growth Trends


(Rs Mn)



EBITDA Profile

EBITDA margin


Rs Mn



PAT Profile

PAT margin

Rs Mn



- *Others include spent oils, Industrial mix solvents
- **Excludes Other Operating Revenue

Financials for the last five years



Summary Statement of Profit and Loss

Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	FY25	H1FY26
Revenue from Operations	4,989	6,835	7,210	7,116	10,300	5,202
Other Income	89	194	240	289	463	325
Total Revenue	5,078	7,029	7,449	7,404	10,762	5,528
Cost of Materials consumed	1,695	2,875	3,360	3,144	4,612	2,408
Employee benefits expenses	290	330	419	532	610	360
Finance costs	53	33	14	2	1	53
Depreciation and amortization	197	221	251	281	178	116
Other expenses	945	1,137	1,240	1,148	1,300	676
Total Expenses	3,178	4,597	5,283	5,106	6,701	3,613
Exceptional Items	(53)	-	-	(97)	-	-
PBT	1,847	2,432	2,166	2,200	4,061	1,916
Tax Expense	489	616	566	563	1,009	483
PAT	1,358	1,816	1,600	1,637	3,052	1,433


Summary Statement of Assets and Liabilities

Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	FY25	H1FY26
I. Assets						
Property, plant and equipment	1,188	1,185	1,282	1,491	2,596	2,599
Other non-current assets	275	466	688	2,041	1,519	2,775
Total non-current assets	1,463	1,651	1,970	3,532	4,116	5,374
Inventories	1,177	1,050	1,257	1,298	2,639	1,968
Trade receivables	1,440	2,274	2,394	1,769	3,495	3,118
Investments (Current)	368	938	1,893	2,355	1,867	2,104
Cash and cash equivalents	611	754	654	410	330	670
Other current assets	304	467	453	1,224	1,728	2,040
Total current assets	3,900	5,483	6,651	7,056	10,059	9,901
Total assets	5,363	7,134	8,621	10,588	14,175	15,275
II. Equity and liabilities						
Total equity	3,398	5,215	6,815	8,452	11,331	12,557
Borrowings	287	-	-	-	-	-
Other non-current liabilities	47	173	67	77	285	307
Total non-current liabilities	334	173	67	77	285	307
Current borrowings	229	-	-	-	-	-
Trade payables	595	565	538	303	891	406
Other current liabilities	807	1,180	1,201	1,757	1,669	2,004
Total current liabilities	1,631	1,745	1,739	2,060	2,559	2,411
Total liabilities	1,965	1,918	1,806	2,136	2,844	2,717
Total equity and liabilities	5,363	7,134	8,621	10,588	14,175	15,275

Shareholder Information



Shareholding as on 30th September 2025



Share Information as on 30th September 2025

NSE Ticker	BLUEJET
BSE Ticker	544009
Market Cap (INR Cr) (BSE)	10,934
% free-float	20.2%
Free-float market cap (INR Cr)	2,207
Cash & Cash Equivalents + Treasury Investment (INR Mn) (As on 30 th September 2025)	3,413
Shares Outstanding	17,34,65,425
3M ADTV (Shares)*	8,08,934
3M ADTV (INR Cr)*	63.1
Industry	Pharmaceuticals

*Source: NSE & BSE

ADTV (Shares): Average Daily Traded Volume


ADTV (INR Cr): Average Daily Traded Value



2

Company at a Glance

Our Journey



Who we are



A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products with an approach of “Collaboration, Development, Manufacturing” to **CDMO** business.



Blue Jet Healthcare at a glance



Key metrics

51¹

Commercialized product
portfolio (FY25)

1,177.9 KL

reaction capacity across
3 facilities (FY25)

INR 10,299.9 mn

Revenue (FY25) (19.9%
FY21-25 CAGR)

INR 3,777.3 mn

EBITDA (FY25) (36.7%
margin)

35.8%

ROCE (FY25)

30.9%

ROE (FY25)

3.97x

Fixed Asset Turnover
(FY25)

INR 2,848 mn

Cash and Cash Equivalents +
Treasury Investments (as of
31st March 2025)

Business Overview



Three product categories:
Contrast Media Intermediates,
High Intensity Sweeteners, and
Pharma Intermediates & Active
Pharmaceutical Ingredients
("API")



Specialised chemistry
capabilities; with dedicated
R&D laboratories



Long-standing relationships
and multi-year contracts with
multi-national customers



Manufacturing facilities
with regulatory
accreditations

Overview of our Product Categories



Overview

End uses

of commercialized products (FY25)

Revenue contribution (FY25)

Client relationships

Contrast Media Intermediates

- Contrast media are agents used in medical imaging to enhance the visibility of body tissues
- Company supplies critical starting intermediate and several advanced intermediates




X-ray & CT Scan



MRI Scan

19



- Top 4 players accounts for ~75% global market share¹
- 4–26 years of relationship with the 3 of the largest manufacturers .


High Intensity Sweeteners

- High-intensity sweetener business involves development, manufacture and marketing of saccharin and its salts

- Table-top sweeteners, oral care products, beverages (primarily soft-drinks), confectionary products, pharmaceutical products, food supplements, and animal feeds



4



- Offers high-intensity sweeteners to over 300 customers globally
- Marquee customers – in FMCG and Agro chemical Space


Pharma Intermediates & APIs

- Collaboration with innovator pharmaceutical companies and multi-national generic companies
- Provides intermediates that serve as pharmaceutical building blocks for APIs in chronic therapeutic areas

- Chronic therapeutic areas such as cardiovascular system (“CVS”), central nervous system (“CNS”), oncology etc



28



- Markets predominantly in regulated markets
- Over 56 customers globally of which 40 in India

Note: ¹ In each of MAT June 2019, 2020, 2021, 2022 and 2023

Source: Company information, IQVIA report dated October 9, 2023 (“Industry Report”)



3

Contrast Media Intermediates

Overview of Contrast Media and its growth drivers



What is contrast media?

- Chemical agents that **enhances the contrast of an imaging modality** in diagnostic imaging, thereby **aiding diagnosis of diseases**
- Once inside the human body, selectively and temporarily taken up by different body tissues
- **Enhance the images, leading to better visualizations of the tissues and organs**

Types of contrast media

- **X-ray / Computed Tomography (CT) contrast agents:** Iodine-based contrast media agents
- **Magnetic Resonance Imaging (MRI) contrast agents:** Gadolinium-based agents
- **Ultrasound (USG) agents:** Stabilized microbubble-based contrast media agents

Growth drivers for contrast media



Growing population and changing demographics

(65 yrs.+) estimated to increase from 6.9% of the total world population in 2000 to 10.4% by 2025¹



Growing prevalence of lifestyle diseases

Such as diabetes, physical inactivity, obesity, etc.



Increased convenience

Through online booking and reporting



Rising healthcare expenditure

Global health expenditure grew at 3.9% CAGR from 2000–17



Focus on early diagnostics


Driven by advancement in diagnostic technologies and growing public awareness



Increasing demand for preventive healthcare

Driven by increased awareness and rising curative costs

The global Contrast Media industry is highly concentrated



Top 4 accounts for ~75% share in 2024



Highly concentrated and dominated by multi-national corporations



Collectively **hold ~75% of the global sales of** contrast media formulations¹



Either **forward integrated** (have equipment manufacturing) or **long-standing relationships with manufacturers**

High entry barriers for key intermediates' vendors



Characteristics of the Contrast Media market



Strict internal standards for product impurity / features profile



Stickiness of relationship




Long-term supply contracts

Blue Jet's positioning

- ✓ More than **two decades of experience**
 - ✓ **75%+ of exports** of a selected contrast media intermediate (**5-Amino-N,N'-bis (2,3-dihydroxypropyl) isophthalamide**) from India¹
 - ✓ Strategically **focused on complex chemistry** categories
-
- ✓ Regularly supplying **key starting intermediate** as the building block
 - ✓ Several **functionally critical advanced intermediates**
 - ✓ **4 to 26** years with 3 of the largest contrast media manufacturers in the world, directly
-
- ✓ **Medium to long term supply contracts** with customers
 - ✓ **~70% of total sales** backed by **contracted** sales volumes²
 - ✓ **Products qualified, approved and validated**

Contrast Media Intermediate product category performance



Continue to forward integrate into more advanced intermediates for Contrast Media



Strong product development and process **optimization capabilities** underpinned by **in-house R&D capabilities**



Focus on molecules with **customer interest** and **strategy** in either **outsourcing or alternate sourcing** the next stage of advanced intermediates



Key starting intermediate as building block in 2000 to **19 additional advanced intermediates** as of FY25



Further **improving chemistry** capabilities in close **synergy** with our customers (**4 to 26** years with 3 of top 4 players directly)

Key benefits

Capture **larger wallet share** with existing customers



Higher realization and profitability per unit



Potential of **moving up the value chain**





4

High Intensity Sweeteners

Blue Jet's positioning in High Intensity Sweetener



Blue Jet's positioning

Products



- Adherence to **strict internal standards** to ensure **consistency in quality, performance, taste, and impurity profile**
- **Multiple products and applications** enabling to cater a **diverse customer base**

Compliance, GMP, supply chain reliability




- **Have received US-FDA inspection report**
- **Semi-automated manufacturing facility**
- **Strong product development and process optimization capabilities**

Customers



- Offers high-intensity sweeteners to over **300 customers globally**
- Focus on **marquee customers** across various sub-sectors
- Table-top sweeteners, oral care products, beverages (primarily soft-drinks), confectionary products, pharmaceutical products, food supplements, and animal feeds

High Intensity Sweeteners product category performance



Sources: Company information



5 Pharma Intermediates & API

Trends and features of the Pharma Intermediates and APIs Product Category



Key trends in Pharma Intermediates and CDMO market

Increased propensity to outsource manufacturing of intermediates & APIs

- Enables **asset light model** and ability to focus on development of **novel products for venture capital backed start-ups**
- Provides **cost advantages** and **supply chain efficiencies**

De-risking dependence on China by global API and formulations players

- Concerns around specific APIs made in China, accentuated with Covid-19
- China **implemented stricter regulations** and witnessed rising wage costs

Self sufficiency with import substitution

- Government initiatives such as **PLI schemes** and **bulk drug parks**
- Growth driven by **proven skills, educational systems, supply chain reliability, and IP protection**

The growth in the global pharmaceuticals market

- Launch of novel therapies (including biologics and personalized therapies)
- Expansion of existing therapies in several geographies
- Growing demand for generic medicines

Revenue and capacity utilization predictability for the CDMO

- Customers prefer close partnerships with CDMO driven by
 - Confidentiality of the projects
 - Novelty of the underlying chemistry and need for custom-development

Features of a typical arrangement to supply of intermediates to innovators of NCEs

Higher realizations per unit sold

- Key criteria for selection of CDMO include track record in the chemistry and similar therapy areas
- Competitive cost is not the most important consideration

Overview of Blue Jet's Pharma Intermediates and APIs Product Category



Salient features

- Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity sweetener business
- Key focus areas include high-value pharma intermediates and APIs
 - In chronic therapeutic areas
 - Import substitution market
- Benefit from collaboration with innovator companies because typical technology transfer reduces the development risk



Client profile

- Innovator pharmaceutical companies and multi-national generic pharmaceutical
- Over 40 customers in India, and 16 globally across Europe, North America, South America, and Asia




Therapeutic areas

- Cardiovascular system ("CVS")
- Oncology
- Central nervous system ("CNS")

Pharma Intermediate and APIs product category performance

CAGR: 82.4%



Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category



Focus on three niche areas in providing CDMO services



Investigational new drugs and new chemical entities (NCEs)

Develop advanced intermediates for NCEs under trials for US-FDA approvals



Drugs that are still under patent and not genericized

Offering advanced intermediates to innovators for four active pharmaceutical ingredients (APIs) which are still under patent

- Including two APIs in the oncology sector, one API in the cardiovascular system category and one API in the central nervous system category



Genericized drugs that are still niche

Offering multiple advanced intermediates to a number of large generics companies for chronic illness therapies

Blue Jet's positioning



Leverage long-standing relationships with innovator companies



Process research, analytical research and chemistry capabilities



Continuous focus on product quality



6

R&D Capabilities

Our R&D framework



R&D capabilities across

Process research

Portfolio
evaluation

Process
development

Process scale-up
and validation

Regulatory filings
and approvals

Analytical research

Literature search

Method
development and
optimization

Characterization of
impurities and
standards

Method validation

Non-carry over
studies

Stability/hold-time
studies

Chemistry research

Polymorphism
screening and
optimization

Pharmaceutical salt
screening and
optimization

Cryogenic reactions

High pressure
reactions

High temperature
reactions

Asymmetric
hydrogenation

Enzymatic
transformations

Particle size
distribution studies

Innovative and complex processes

Catalytic
hydrogenation

Iodination

Bromination

Chlorination

Diazotization

Esterification

Hoffman
re-arrangement

Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint

Invested in windmills with
installed capacity of 3.3MW



Created carbon sinks
through tree plantations



Focus on enhancing
energy efficiency



Effluent treatment plants with
modern standards of flocculation,
clarification and aeration



Minimizing solvents and
using recycled solvents
and water






7

Growth Strategy

Our strategies





8

Management and Board of Directors

Experienced and visionary management team backed by independent - Board of Directors



Management team



**Akshay Bansarilal
Arora**
Executive Chairman

- Has more than three decades of experience with the Company
- Holds bachelor's and master's degrees in science from University of Mumbai



**Shiven Akshay
Arora**
Managing Director

- Has more than six years of experience with the Company
- Holds a bachelor's degree in business from Bond University, Gold Coast, Australia



Naresh Suryakant Shah
Executive Director, Head
– Marketing

- Has more than three decades of experience in marketing
- Currently also associated as a director of BC Bio Sciences
- Holds a diploma in Chemical Engineering from the Khopoli Polytechnic College, Raigad



**Ganesh
Karuppannan**
Chief Financial Officer

- Previously worked with Philips Electronics, Dr. Reddy's Laboratories, Granules as CFO
- Associate member of Institute of Chartered Accountants of India since 1988



**Vimalendu Kumar Singh
(V.K. Singh)**
Chief Operating Officer

- Previously worked with Strides Pharma, Emcure Pharmaceuticals, RPG Life Sciences, and Ranbaxy Laboratories
- Has a bachelor's degree in chemical engineering from IIT Kanpur and a master's programme from IIFT, New Delhi



Chandrashekar Parenky
President – Research and
Development

- Previously worked at Amoli Organics and Kores (India) as CEO
- Holds a doctorate of philosophy in science from the University of Bombay and a master's degree from Birla Institute of Technology & Science

Experienced and visionary management team backed by independent Board of Directors (cont'd)



Management team (cont'd)



Popat B Kedar
Executive Director

- Holds a Bachelor's and Master's degree in Science, specializing in Inorganic Chemistry from Shivaji University, Kolhapur.
- Has over 34 years of experience as a Plant Manager, previously working with Infotech Pharma Pvt. Ltd., Godavari Drugs Pvt. Ltd., and Sara Research Centre.
- Associated with the company since July 2005 and served as a Director at Blue Jet Healthcare Limited from December 31, 2020, to February 1, 2022.



Sweta Poddar
Company Secretary and
Compliance Officer

- Has experience of over a decade as a company secretary
- Associated with Chinara Chemicals Private Ltd. and Aarey Drugs and Pharmaceuticals Ltd.
- Holds a bachelor's degree in commerce from the University of Calcutta



**Girish Paman
Vanvari**
Independent Director

- Founder and Partner of Transaction Square LLP and Valuation Square LLP. He is the member of Institute of Chartered accountants of India.
- Has experience in tax, regulatory, and business advisory functions
- Holds a bachelor's degree in commerce from Shri Narsee Monjee College of Commerce and Economics
- Other Directorships held: Tarsons Products Ltd, Aurbindo Pharma Ltd, Himadri Specialty Chemical Ltd, Kolte Patil Developers Ltd



**Preeti Gautam
Mehta**
Independent Director

- Practicing advocate & solicitor and a senior partner of Kanga & Co
- Over 30 years of experience in corporate laws, foreign investments, M&A & PE investments, banking, franchising, and hospitality
- Other Directorships held: Sumitomo Chemicals Ltd, Prpten - E Gov Technologies Ltd, JCB India Ltd



**Divya Sameer
Momaya**
Independent Director

- Holds a bachelor's degree in commerce from the University of Pune
- Partner of D. S. Momaya & Co. LLP and first director of MMB Advisors Private Limited
- Previously worked with BSE Limited and BSEL Infrastructure Realty Limited
- Other Directorships held: GTPL Hathway Ltd, Motilal Oswal Financial Services Ltd, Motilal Oswal Home Finance Ltd



Priyanka Yadav
Independent Director

- Ms. Priyanka Yadav, a Fellow Member of ICSI, holds bachelor's, master's, and law degrees from the University of Mumbai.
- She leads Priyanka Yadav & Associates with 6+ years of experience in corporate laws, NCLT matters, and compliance.
- An expert in listing compliance, IPOs, and corporate restructuring, she advises on governance and legal due diligence.

Thank you!

BLUE JET HEALTHCARE LIMITED



Registered Office

701,702, 7th Floor, Bhumi Raj Costarica,
Sector 18, Sanpada, Navi Mumbai Thane
400705, Maharashtra, India



NSE: BLUEJET, **BSE:** 544009

ISIN: INE0KBH01020

Website: www.bluejethealthcare.com

INVESTOR RELATIONS AT



Blue Jet Healthcare Limited

Sanjay Sinha, Deputy Chief Financial Officer
sanjay.sinha@bluejethealthcare.com



Kunal Bhoite
kunal.bhoite@in.ey.com

Advait Bhadekar
advait.bhadekar@in.ey.com